<DOC>
	<DOCNO>NCT00004008</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bryostatin 1 treat patient ovarian epithelial cancer respond previous chemotherapy .</brief_summary>
	<brief_title>Bryostatin 1 Treating Patients With Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate antitumor activity toxicity bryostatin 1 patient platinum resistant ovarian epithelial cancer . - Determine response rate patient treat regimen . OUTLINE : This multicenter study . Patients receive bryostatin 1 IV 24 hour . Treatment repeat weekly 8 course absence disease progression unacceptable toxicity . Patients achieve stable regressive disease may receive additional treatment . Patients follow least 4 week treatment , every 3 month . PROJECTED ACCRUAL : A total 14-25 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven ovarian epithelial cancer Progressive disease completion least one platinum base chemotherapy regimen Bidimensionally measurable disease At least 2 cm xray , CT scan , ultrasound No active , symptomatic brain metastasis ( e.g. , cerebral edema and/or progressive tumor growth ) PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 12 week Hematopoietic : Hemoglobin least 10 g/dL WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.7 mg/dL AST/ALT great 2.5 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 1.4 mg/dL Other : No active , uncontrolled infection No nonmalignant systemic disease would increase risk patient No malignancy within past 5 year except curatively treat basal squamous cell skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week since nitrosoureas mitomycin ) recover No 2 prior multidrug chemotherapy regimens No 1 prior single agent chemotherapy regimen Endocrine therapy : At least 4 week since prior endocrine therapy recover No concurrent steroid Concurrent hormone replacement therapy allow Radiotherapy : At least 4 week since prior radiotherapy ( exclude palliative therapy ) recover No concurrent radiotherapy Surgery : At least 4 week since prior major thoracic abdominal surgery Other : No concurrent anticancer therapy investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>